4.7 Review

A Systematic Review of Nutritional Lab Correlates with Chemotherapy Induced Peripheral Neuropathy

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Oncology

Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

Hannah C. Timmins et al.

Summary: Metabolic syndrome and associated conditions have been identified as potential risk factors for chemotherapy-induced peripheral neurotoxicity (CIPN). Obesity and low physical activity may contribute to the development of CIPN. Further research is needed to explore CIPN risk factors and determine if lifestyle changes can improve long-term outcomes for cancer survivors.

JOURNAL OF CANCER SURVIVORSHIP (2023)

Article Oncology

Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer

K. A. Nyrop et al.

Summary: Black and White women with early breast cancer had similar symptom severity during chemotherapy, except for lymphedema and peripheral neuropathy. Dose reductions were more common in Black patients in non-anthracycline regimens. Minimal differences were observed in patient-reported symptoms and adverse outcomes between Black and White patients in this study.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Article Oncology

The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors

Hannah C. Timmins et al.

Summary: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side effect of neurotoxic cancer treatment, and this study aimed to evaluate the association between being overweight (BMI >= 25 kg/m(2)) and worse symptomatic, clinical, and functional CIPN outcomes. Overweight patients showed significantly worse CIPN compared to those with a normal BMI, with factors like age, waist circumference, and body surface area being associated with CIPN severity.

JOURNAL OF CANCER SURVIVORSHIP (2022)

Article Medicine, General & Internal

Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy

David Mizrahi et al.

Summary: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating adverse effect of neurotoxic cancer treatments, and this study suggests that participants with low pretreatment hemoglobin, higher body mass index, older age, and female sex were more likely to develop CIPN posttreatment after receiving paclitaxel or oxaliplatin chemotherapy. Future research should explore whether these risk factors are associated with a higher incidence of CIPN development.

JAMA NETWORK OPEN (2021)

Review Clinical Neurology

Nutritional neuropathies

Kelly G. Gwathmey et al.

MUSCLE & NERVE (2020)

Article Oncology

Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin

Nilgun Yildirim et al.

SUPPORTIVE CARE IN CANCER (2020)

Article Oncology

Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy

Theodore S. Jennaro et al.

BREAST CANCER RESEARCH AND TREATMENT (2020)

Review Biochemistry & Molecular Biology

Mechanisms of Chemotherapy-Induced Peripheral Neuropathy

Renata Zajaczkowska et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Article Clinical Neurology

Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients

Jetter Robertson et al.

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2018)

Article Biology

Quantifying publication bias in meta-analysis

Lifeng Lin et al.

BIOMETRICS (2018)

Article Nutrition & Dietetics

Selected Risk Nutritional Factors for Chemotherapy-Induced Polyneuropathy

Jiri Grim et al.

NUTRIENTS (2017)

Article Clinical Neurology

Serum micronutrients and prealbumin during development and recovery of chemotherapy-induced peripheral neuropathy

Roser Velasco et al.

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2016)